Segment Information

9 Months Ended

Jan. 31, 2015

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

Note 9. Segment Information

The Company operates in two reportable segments, POS and TOS. The accounting policies of the Company’s segments are the same as those described in Note 2 of the Company’s annual financial statements for the year ended April 30, 2014, as filed on Form 10-K. The Company evaluates performance of its segments based on profit or loss from operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes (“segment profit”). Management uses segment profit information for internal reporting and control purposes and considers it important in making decisions regarding the allocation of capital and other resources, risk assessment, and employee compensation, among other matters. The following tables summarize, for the periods indicated, operating results by reportable segment (in thousands):

	Personalized		Translational
	Oncology		Oncology		Unallocated
	Solutions		Solutions		Corporate
Three Months Ended January 31, 2015	(POS)		(TOS)		Overhead		Consolidated
Net revenue	$	453	$	1,376	$	-	$	1,829
Direct cost of services		(672)		(1,300)		-		(1,972)
Sales and marketing costs		(366)		(613)		-		(979)
Other operating expenses		-		(1,028)		(612)		(1,640)
Stock- based compensation expense (1)		-		-		(657)		(657)
Segment profit (loss)	$	(585)	$	(1,565)	$	(1,269)	$	(3,419)

	Personalized		Translational
	Oncology		Oncology		Unallocated
	Solutions		Solutions		Corporate
Three Months Ended January 31, 2014	(POS)		(TOS)		Overhead		Consolidated
Net revenue	$	590	$	3,100	$	-	$	3,690
Direct cost of services		(608)		(1,007)		-		(1,615)
Sales and marketing costs		(405)		(352)		-		(757)
Other operating expenses		-		(531)		(1,254)		(1,785)
Stock- based compensation expense (1)		-		-		(941)		(941)
Segment profit (loss)	$	(423)	$	1,210	$	(2,195)	$	(1,408)

	Personalized		Translational
	Oncology		Oncology		Unallocated
	Solutions		Solutions		Corporate
Nine Months Ended January 31, 2015	(POS)		(TOS)		Overhead		Consolidated
Net revenue	$	1,245	$	4,377	$	-	$	5,622
Direct cost of services		(2,171)		(3,205)		-		(5,376)
Sales and marketing costs		(1,243)		(1,650)		-		(2,893)
Other operating expenses		-		(3,490)		(2,413)		(5,903)
Stock- based compensation expense (1)		-		-		(2,284)		(2,284)
Segment profit (loss)	$	(2,169)	$	(3,968)	$	(4,697)	$	(10,834)

	Personalized		Translational
	Oncology		Oncology		Unallocated
	Solutions		Solutions		Corporate
Nine Months Ended January 31, 2014	(POS)		(TOS)		Overhead		Consolidated
Net revenue	$	1,834	$	7,258	$	-	$	9,092
Direct cost of services		(2,078)		(2,572)		-		(4,650)
Sales and marketing costs		(1,159)		(812)		-		(1,971)
Other operating expenses		-		(1,595)		(2,790)		(4,385)
Stock- based compensation expense (1)		-		-		(1,968)		(1,968)
Segment profit (loss)	$	(1,403)	$	2,279	$	(4,758)	$	(3,882)

(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.

All of the Company’s revenue is recorded in the United States and substantially all of its long-lived assets are in the United States.